CommercialCoverageLow impact
Drug Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Oncology, Hematology·Pharmacy
Effective date
Mar 8, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated drug policy criteria for two medications: Journavx indication questions were updated to match new labeling, and a new biosimilar Filkri (filgrastim-laha) was added to the formulary alongside existing Neupogen and filgrastim biosimilars.
Action Required
By March 8, 2026: Billing team should verify that Filkri (filgrastim-laha) is properly coded in billing system and review any prior authorization requirements for Journavx to ensure updated indication questions are addressed. Confirm formulary tier placement for each plan type (Complete, Essential, Standard, Metallic).